Prialt

Prialt (also known as Ziconotide) is a non-opioid analgesic used for the management of severe chronic pain. It is derived from the venom of the marine cone snail species Conus magus.

History

Prialt was developed by Elan Corporation and approved by the FDA in December 2004. It is the first in a new class of pain medications that work by blocking N-type voltage-sensitive calcium channels.

Mechanism of Action

Prialt works by blocking N-type voltage-sensitive calcium channels on the primary nociceptive (pain) pathways in the brain. This prevents the release of pain neurotransmitters in the brain, thereby reducing the sensation of pain.

Administration

Prialt is administered through intrathecal administration, which involves injection into the spinal fluid. This method of administration is used because Prialt does not cross the blood-brain barrier well.

Side Effects

Common side effects of Prialt include dizziness, nausea, confusion, and headache. Severe psychiatric symptoms and neurological impairment may occur if the drug is stopped abruptly.

See Also

• Analgesic
• Ziconotide
• Conus magus
• Elan Corporation
• Food and Drug Administration
• N-type calcium channel
• Intrathecal administration
• Blood-brain barrier

‎